VBLT earnings

- Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol "NTBL" effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned operations into 2025 - - Completed previously announced $10.3 million private placement with leading healthtech-focused investors, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund - - Predictive Precision Medicines Platform ("PPMP") applied to select and develop two clinical-stage therapeutic candidates with lead programs in acute myeloid leukemia ("AML"); four Phase 2 milestones expected by 1Q 2025 including Phase 2a results for lead asset Volasertib in

Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable's proprietary Predictive Precision Medicines Platform ("PPMP") Notable's validated PPMP combines multi-dimensional biological assays and machine learning to bio-simulate a patient's cancer treatment and predict their clinical response to the actual treatment Notable has applied its PPMP to selecting and developing two clinical-stage therapeutic candidates in acute myeloid leukemia ("AML"); Phase 2a results for lead asset Volasertib in adult AML in platform-predicted responding patients expected in 3Q 2024 Leading healthtech-focus

OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023 Conference Call and Webcast at 8:30 a.m. ET Today TEL AVIV, Israel and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced financial results for the first quarter ended March 31, 2022, and provided a corporate update. "We continue to execute on our development and strategic objectives, which we believe have positioned us for a potentia

TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it will release first quarter financial results for the period ended March 31, 2022 on Tuesday, May 17 before market open. Professor Dror Harats, M.D, Chief Executive Officer, and Sam Backenroth, Chief Financial Officer, will host a conference call at 8:30am ET to discuss the results and provide a corporate update. Call Details:Tuesday, May 17, 2022 at 8:30am ETConference ID: 13729281US: 1-877-407-

OVAL top-line data for ofra-vec progression free survival (PFS) primary endpoint expected in 2H 2022; with positive results, VBL anticipates submitting a Biologics License Application (BLA) in 1H 2023 Completed patient enrollment in the 409 patient OVAL Phase 3 registration enabling trial investigating ofra-vec in patients with platinum-resistant ovarian cancerPreliminary data from ofra-vec Phase 2 trials in mCRC and rGBM expected in 2022VB-601, a monoclonal antibody targeting monocytes for prevalent and chronic inflammatory disorders, expected to enter the clinic in 2H 2022KOL event in NYC to discuss ofra-vec in ovarian cancer planned for April 11, 2022Conference Call and Webcast at 8:30 a.

TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it will release financial results for the year ended December 31, 2021 on Wednesday, March 23 before market open. Professor Dror Harats, M.D., Chief Executive Officer, and Sam Backenroth, Chief Financial Officer, will host a conference call at 8:30am ET to discuss the results and provide a corporate update. Call Details:Wednesday, March 23, 2022 at 8:30am ETConference ID: 13727878US: 1-877-407-

Conference Call and Webcast at 8:30 a.m. ET Today Data from multiple VB-111 clinical trials expected in 2022, including the progression free survival (PFS) co-primary endpoint from the Phase 3 OVAL study expected in the second half of 2022More than 85% of the planned 400 patients in the OVAL Phase 3 study evaluating VB-111 in platinum resistant ovarian cancer have been enrolled; remains on track to complete enrollment in the first quarter of 2022VB-601, a monoclonal antibody targeting monocytes for prevalent and chronic inflammatory disorders, expected to enter the clinic in the second half of 2022 TEL AVIV, Israel and NEW YORK, Nov. 15, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:

TEL AVIV, Israel and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it will release third quarter financial results for the period ended September 30, 2021 on Monday, November 15 before market open. Professor Dror Harats, M.D, Chief Executive Officer, and Sam Backenroth, Chief Financial Officer, will host a conference call at 8:30am ET to discuss the results and provide a corporate update. Conference Call:  Monday, November 15, 2021 at 8:30am ET Conference ID: 10017250 US: 855-327-6837 I

TEL AVIV, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) will release its second quarter financial results for the period ended June 30, 2021 on Monday, August 16 before market open. Professor Dror Harats, M.D, Chief Executive Officer and Amos Ron, Chief Financial Officer, will host a conference call at 8:30am EDT the same day to discuss the results and provide a corporate update. Conference Call: Monday, August 16, 2021 at 8:30am EDTConference ID: 13721456 US: 1 877 407 9208 Israel Local: 1 809 406 247 International: 1 201 493 6784 Webcast: https://edge.media-server.com/mmc/p/9trg9snq    About VBLVascular Biogenics Ltd., operating as VBL Therapeutics, is a public